News | February 02, 2024
Vimta Labs posts Q3 FY24 consolidated PAT at Rs. 10.13 Cr
Vimta Labs has reported total income of Rs. 82.57 crores during the period ended December 31, 2023
Vimta Labs has reported total income of Rs. 82.57 crores during the period ended December 31, 2023
Morepen Laboratories has reported total income of Rs. 448.62 crores during the period ended December 31, 2023
Sun Pharmaceutical Industries has reported total income of Rs. 12,630.9 crores during the period ended December 31, 2023
This Phase III clinical trial is a randomized, double-blind, placebo-controlled, multicenter clinical trial in China to evaluate the safety and efficacy of ASC40
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Novartis India has reported total income of Rs. 106.50 crores during the period ended December 31, 2023
Astec LifeSciences has reported total income of Rs. 51.70 crores during the period ended December 31, 2023
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Gabapentin is indicated for the management of Postherpetic Neuraligia
Laurus Labs has reported total income of Rs. 1197.35 crores during the period ended December 31, 2023
Subscribe To Our Newsletter & Stay Updated
